NCT06561425 (Atalanta-1) is a Phase 1, PHASE2 clinical trial of GLPG5101 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, sponsored by Galapagos NV.

Who is sponsoring NCT06561425?

NCT06561425 is sponsored by Galapagos NV.

What drugs are being tested in NCT06561425?

Interventions in NCT06561425: GLPG5101.

What condition does NCT06561425 study?

NCT06561425 studies Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell.

Is NCT06561425 still recruiting?

NCT06561425 is currently active, enrolled. Last updated 16 March 2026.

Last reviewed 2026-03-16 · How we verify

NCT06561425: Atalanta-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

Active, enrolled Phase 1, PHASE2 Last updated 16 March 2026

What this trial tests

Phase 1, PHASE2 trial testing GLPG5101 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma in 130 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 March 2022

Primary endpoint
1 July 2029

1 July 2029

Quick facts

Lead sponsor	Galapagos NV
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	130
Start date	9 March 2022
Primary completion	1 July 2029
Estimated completion	1 July 2029
Sites	10 locations across Belgium, Netherlands, United States

Drugs / interventions tested

GLPG5101

Conditions studied

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma — all drugs for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma →
Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell — all drugs for Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell →

Sponsor

Galapagos NV — full company profile →

Who can join

18 and older, any sex, with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first phase is to see which doses of GLPG5101 work best with the least number of side effects. * In the second phase, participants will receive the selected dose(s) based on the results in the first phase.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells.
Boccellato E, Comba L, Tavarozzi R, Castellino C, et al · · 2025 · cited 2× · PMID 40647536 · DOI 10.3390/cancers17132239
Are we there yet? The road to faster and more efficient CAR T cell manufacturing.
Matos LN, Costa MS, Serra M, Costa MHG. · · 2026 · cited 1× · PMID 41862931 · DOI 10.1186/s13036-026-00666-5
Molecular Pathogenesis and Targeted Treatment of Richter Transformation
Maher N, Karami A, Matti B, Alwan A, et al · · 2026
Plenary Abstracts Session & Oral Presentations
· 2025

Verify or expand the search:

Other recruiting trials for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07376642 — A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, · EARLY_PHASE1 · recruiting
NCT07073833 — The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma · Phase 1 · recruiting

Other Galapagos NV trials

Trials by the same sponsor.

NCT06043739 — Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects · Phase 1 · completed
NCT05856448 — A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lup · Phase 2 · completed
NCT05479058 — A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission · Phase 3 · terminated
NCT05335447 — Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667 · Phase 1 · completed
NCT05272683 — Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06561425 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Galapagos NV
Last refreshed: 16 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06561425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing